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Abstract 
The effects of the E1A protein of adenovirus-5 onthe differentiation program of F9 teratocarcinoma cells were examined by the stable 
introduction ofplasmids that expressed wild-type or mutated forms of E1A. Constitutive expression of plasmids for most of the mutant 
E1As induced loss of expression of the cell-surface antigen SSEA-I and the enhanced expression of genes pecific for the differentiated 
phenotype ofF9 cells, such as genes for laminin B 1, tissue-type plasminogen activator (tPA) and type IV collagen, as well as the altered 
cell morphology that is associated with the differentiated state. However, such changes were not observed inthe case of genes for mutant 
proteins from which a conserved region (CR1) of E1A had been deleted. Furthermore, no significant induction of expression of the c-jun 
gene or transactivation f the c-jun-CAT reporter gene were observed when the sequence that encodes CRI of EIA had been deleted. A
palindromic sequence element (DRE) of the c-jun promoter was essential for the E1A-mediated up-regulation f the c-jun gene. These 
results imply that CR1 is required for activation of the c-jun gene and that it is implicated in the growth arrest, expression of parietal 
endoderm-specific functions and the orderly differentiation f F9 cells. 
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1. Introduction 
The product of an early-region gene of adenovirus-5, 
E1A, can be detected as differentially spliced transcripts, 
namely, 12S and 13S mRNAs, that encode proteins of 243 
and 289 amino acids, respectively. Comparison of E1A 
proteins from different adenovirus serotypes has led to the 
identification of three highly conserved regions (CR1, CR2 
and CR3). The sequences encoding CRI and CR2 are 
found in both 12S and 13S mRNAs, whereas the sequence 
that encodes CR3 is found only in the 13S mRNA [1-4]. 
Mutational analysis has demonstrated that these three con- 
served regions correspond to major, distinct functional 
domains within E1A proteins [4,5]. The transformation a d 
immortalization functions of E1A protein have been local- 
ized to the sequences of CR1 and CR2 [6-10]. The third 
conserved omain, CR3, functions as an activator of the 
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transcription of many viral and cellular promoters [ 11-15]. 
However, no evidence has been presented that any E1A 
protein binds to DNA in a sequence-specific manner or 
that it functions as a transcription factor. 
The multiple functions of E1A proteins derive from the 
combinatorial presence within the E1A proteins of three 
distinct regions, which bind to different cellular proteins, 
such as p300, p130, p107, p105 RB (the product of the 
retinoblastoma susceptibility gene; abbreviated as pRB), 
p60Cyctin A, p33cdk2 and several unidentified polypeptides, 
in infected or transfected cells [16-18]. Such binding 
affects a variety of cellular pathways via alterations in the 
control of cell growth and the regulation of transcription 
[19-25]. The amino acid motifs found in CR1 and CR2 of 
E1A are required for binding to the 105kDa protein pRB 
[ 10] and to pRB-related proteins p107 and p 130 [21,26-29]. 
It has also been reported that pRB and pRB-related pro- 
teins can, in association with the transcription factor E2F, 
modulate the cell cycle [30-34]. E2F is one of the modula- 
tors of the viral E1A-dependent transcription of certain 
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viral and cellular genes that contain E2F-binding sites. 
Activation of transcription from the various promoters by 
E1A is correlated, at least in part, with the ability of E1A 
protein to cause the release of E2F from inactive com- 
plexes with other cellular proteins, which include com- 
plexes with pRB [35]. Recent studies have confirmed that 
pRB represses E2F-dependent transcription and that E1A 
proteins prevent this repression by disrupting the pRB-E2F 
complexes [36]. 
The p300 protein is a nuclear phosphoprotein [23,24] 
with DNA-binding activity [37] that is thought to act as a 
transcription factor. Recently Eckner et al. reported that 
the p300 protein overcomes the repressive ffect of EIA 
on the SV40 enhancer, a property that suggests that it 
might function as a transcriptional daptor protein [38]. 
The region of E1A required for binding to p300 includes 
residues at the amino terminus of E1A that are indepen- 
dent of the pRB-binding site. Thus it seems possible that 
E1A acts via a distinct mechanism toregulate transcription 
[19-22]. Moreover, it was reported recently that the E1A 
protein inhibits the phosphorylation f p300 [39]. 
F9 cells [40] are teratocarcinoma cells that are often 
used as a model system for studies of gene regulation 
during early mammalian development [41-43]. It has been 
demonstrated that the E1A protein is capable of influenc- 
ing the differentiation of 1:'9 cells, with expression of the 
EIA protein altering both the phenotype of the cells and 
the pattern of cellular gene expression [44,45]. 
The proto-oncogene c-jun encodes a nuclear protein 
that forms homodimeric or heterodimeric complexes with 
the products of the fos gene family to regulate transcrip- 
tion of target genes by binding to a specific DNA sequence 
in the promoter egion [46]. Studies of the expression of 
c-jun indicate that it is rapidly~and transiently induced by 
growth factors or tumor promoters in a variety of cell 
types [47-53], and the increased expression of c-jun is 
observed uring E1A-mediated ifferentiation of F9 cells 
[47,51-53]. Furthermore, ctopic expression of the c-jun 
gene results in differentiation of embryonic arcinoma 
(EC) cells, such as F9 and P19 cells [48-52], suggesting 
that the induction of transcription of the c-jun gene by 
E1A plays an important role in the differentiation process. 
To investigate the molecular mechanisms responsible 
for the inductive ffects of E1A on the differentiation of
F9 cells and, in addition, to identify the conserved omain 
of E1A that influences cellular gene expression to bring 
about he differentiation 1' F9 cells, we have used mutant 
derivatives of adenovirus-5 E1A that lack conserved re- 
gions and the amino terminus, namely, regions to which 
the functions of E1A have been mapped [14,23-25]. Phe- 
notypic alterations and altered expression of several mark- 
ers of differentiation, such as SSEA-1, laminin B1, colla- 
gen type IV and tPA, were observed in F9 cells that 
expressed these mutants E1As, except in the case of the 
mutant E1A without a CR1 (A51-116). In addition, the 
transcription of the c-jun gene was induced in E1A trans- 
formants, except in the case of the mutant E1A without a 
CRI (A51-116). These results suggest hat expression of 
endodermal phenotypes and the process of differentiation 
are dependent upon factors whose function is induced, 
directly and indirectly, by CR1 of E1A. 
2. Materials and methods 
2.1. Cells and plamids 
F9 cells were maintained in Dulbecco's modified 
Eagle's medium (DMEM; Nissui, Tokyo, Japan) supple- 
mented with 10% fetal bovine serum (GIBCO BRL, Grand 
Island, NY), 0.6 mg/ml L-glutamine (Sigma Chemical 
Co., St. Louis, MO), 100 U/ml penicillin G (GIBCO 
BRL) and 100 /xg/ml streptomycin (GIBCO BRL). The 
plasmid pSVEIA (encoding wild-type E1A of adenovirus 
type-5) and several truncated mutant forms of pE1A, in- 
cluding pE1A A15-35, pE1A A51-116, pE1A A81-120, and 
pEIAA121-150, all driven from SV40 promoter, were 
generously provided by Dr. E. Moran [14]. Plasmids en- 
coding laminin B1, collagen type IV, tPA and fl-actin 
were obtained from Gene Bank, RIKEN. The reporter 
plasmids encoding c-jun-CAT constructs [ - 730/+ 874c- 
jun-cat and - 7 30 / + 87 4c-jun-C A Tm182 /17 5(mDRE) ] 
have been described elsewhere [53]. 
2.2. Northern and Southern blotting 
Total cellular RNA was prepared by the guanidine 
isothiocyanate method [54]. Twenty/xg of total RNA were 
subjected to electrophoresis on a 1.1% formal- 
dehyde/formamide-agarose gel and blotted onto a Hy- 
bond-N + membrane (Amersham Japan, Tokyo). Hy- 
bridization was carried out with a DNA probe that had 
been radiolabeled using an oligo-primed labeling kit 
(Amersham Japan) at 42 ° C for 18 h [55]. Southern blotting 
was performed as described elsewhere [54], and the hy- 
bridization with DNA blots was allowed to proceed for 20 
h at 65 ° C. Washing of membranes and autoradiography 
were performed as described elsewhere [54]. 
2.3. Radiolabeling of cells, immunoprecipitation and 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) 
Cells were radiolabeled by incubation for 4 h with 
[35S]methionine (50 mCi/ml; Amersham, Japan) in me- 
thionine-free DMEM or with [32p]orthophosphate (40 
mCi/ml; Amersham, Japan) in phosphate-free DMEM that 
contained 5% dialyzed fetal bovine serum. The cells (2.4 
× 10 s) were lysed by incubation at 4 ° C for 30 min in 1 
ml of lysis buffer [20 mM sodium phosphate (pH 7.0), 250 
mM NaC1, 30 mM sodium pyrophosphate, 0.1% NP-40, 5 
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mM EDTA, 10 mM NaF, 0.1 mM Na3VO 4, and I mM 
phenylmethanesulfonyl fluoride (PMSF)] supplemented 
with 1 /zg/ml leupeptin, 0.5 /zg/ml pepstatin and 1 
/zg/ml aprotinin. Then 200 /xl of the supematant of the 
cell lysate were incubated with 10-100/zl of a solution of 
monoclonal antibody at 4 ° C for 12 h, with subsequent 
agitation with 25 /zl of a suspension of protein A-Sep- 
harose beads (Pharmacia-LKB Biotechnology, Uppsala, 
Sweden) at 4 ° C for 2 h. The beads were washed 4 times 
with 1 ml of lysis buffer and the adsorbed proteins were 
dissociated by boiling for 5 min in 25 /zl of sample buffer 
and analyzed by SDS-PAGE [56,57]. The gel was dried 
and exposed to X-ray film at - 80 ° C. 
2.4. Western blot analysis 
Proteins extracted from the various lines of cells gener- 
ated in this study were subjected to electrophoresis on 
2-15% gradient SDS-polyacrylamide g ls and transferred 
to Immunobilon PVDF-nylon membranes (Daiichi Pure 
Chemicals Co., Tokyo, Japan) with the Fastblot, rapid 
semi-dry blotting system from Biometra (Postfach, Ger- 
many), as described by the manufacturer. Mouse mono- 
clonal antibodies against E1A (M73; Oncogene Science 
Inc., Uniondale, NY) and rabbit antibody against c-jun and 
horseradish peroxidase-conjugated (HRP-conjugated) anti- 
bodies against mouse IgG or rabbit IgG were used for 
immunodetection. Bands were visualized with a Chemilu- 
minescence Renaissance kit (DuPont NEN, Boston, MA). 
2.5. FACS analysis of the cell-surface antigen SSEA-1 
Cells were harvested by incubation in 10 mM phos- 
phate-buffered saline [PBS(-)] that contained 5% FCS 
and 0.5 M EDTA at 37 ° C for 30 min, and then they were 
washed twice in PBS(-)  that contained 3% FBS and 
analyzed for the expression of SSEA-1 antigen, which is 
specifically expressed on embryonal stem cells [58], by 
single-color flow cytometry on a FACScan (Becton Dick- 
inson, Mountain View, CA). The following antibodies 
were used for staining: first antibody, monoclonal ntibody 
against SSEA-I (stage-specific embryonal antigen; KM- 
380; Kyowa Medex Co., Tokyo), or, as a control, mouse 
normal preimmune serum; second antibody, a mixture of 
FITC-conjugated rabbit F(ab')2 against mouse immuno- 
globulin (Becton Dickinson). Dead cells were gated out by 
forward scattering and monitored by staining with propid- 
ium iodide. 
2.6. Determination of growth rate 
A total of 5 X l 0  4 cells was plated per 100-mm culture 
flask and, on four consecutive days, cell numbers were 
counted with a hemocytometer after trypsinization. 
2.7. Transfection and assays of chloramphenicol acetyl- 
transferase (CAT) and fl-galactosidase activities 
Cells were plated at 5 × 105 cells per 100-mm dish, 24 
h prior to transfection, and they were transfected with 2 
Amino acid 
Name of clone sequence 
WT 
mA 
CR1 CR2 CR3 
E1A, wildtype N [ L.~.., . ........... 
37 80 121 139 188 
p300-binding site ~ 
3. 25 68 85 
pRB-binding site ...... 
37 50 121 127 
E1A A(15-35) 
15 35 
mB EIA A(51-116) 
IC 
289 
mC EIA A(81-120) 
mD E1A A(121-151) ~ I 
121 151 
Fig. 1. Schematic representation f products of clones of the wild-type and mutant genes that encode EIA. The E1A region is composed of three domains 
(CR1,CR2,CR3) with relatively strong similarity. The positions of the mutations discussed in the text are indicated by amino acid positions in the 
289-amino acid product of the wild-type E1A. Deleted sequences are indicated by black regions. The binding regions of p300 and pRB proteins are 
indicated [58,59]. WT, Wild-type cDNA for Ad-5 13S EIA protein. 
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/a,g of RSVneo [53], 2 tzlg of pCHl l0 [59], 6 p,g of 
c-jun-CAT reporter plasmid, and 10/zg of wild-type pE1A 
or a mutant construct by the calcium phosphate co-precipi- 
tation procedure [54]. After selection with 500 /xg/ml 
G418 for more than two weeks, G418-resistant cells were 
cloned and analyzed by the CAT assay. Activities of CAT 
and /3-galactosidase were assayed and the ratio of the 
activity of CAT to that of /3-galactosidase was used for 
normalization as described elsewhere [53]. In some experi- 
ments, F9 cells were incubated with retinoic acid (RA; 
1 X 10 -6 M) for 72 h and analyzed for CAT activity and 
the expression of mRNA as described elsewhere [53]. 
3. Results 
3.1. Isolation of F9 clones that expressed mutant EIA 
proteins 
Constructs were used that encoded E1A proteins with 
mutations in each of the three conserved regions, as well 
as at the amino-terminus. The construction of these E1A 
mutants and the biological properties of the altered prod- 
ucts of the E1A gene have been described elsewhere 
[4,10,21]. Each construct (see Fig. 1) was used to transfect 
F9 cells together with pRSVneo, a plasmid that confers 
resistance to G418. G418-resistant clones were isolated, 
propagated and analyzed for expression of E1A. After 
more than two weeks of ,;election in medium that con- 
tained G418, we obtained fi'om several dozen to about one 
hundred clones. Each EIA mutant clone was established 
by a standard re-cloning procedure. Southem blot analysis 
of DNA isolated from single colonies indicated the pres- 
ence of integrated E1A sequences and, moreover, it 
demonstrated that each clone was the result of an indepen- 
dent event. The number of copies of the E1A gene varied 
from one to ten copies per cell (data not shown). We 
selected and established as clones only those that had one 
copy of the gene per cell for analysis of the expression of 
EIA mRNA. The cells isolated from transfections with 
cDNA plasmids that encoded mutant E1As, all expressed 
mRNAs of the expected sizes (data not shown). We next 
examined the presence of l:he E1A proteins in these cells 
by immunoprecipitation with an E1A-specific antibody. 
Some F9 clones that expressed significant levels of E1A 
mRNA also contained etectable vels of the correspond- 
ing protein (data not shown). 
The clones transfected with the wild-type E1A plasmid 
yielded only rare colonies, a result that corresponds to a 
previously reported observation [45,60]. Although we do 
not know the exact reasons for this result, the wild-type 
E1A protein could be toxic, per se, to the F9 cells, in 
which case only clones that expressed low levels of EIA 
protein would be expected to survive. It is also possible 
that the promoter of each plasmid was down-regulated in 
undifferentiated F9 cells. 
3.2. Cells with mutant E1A proteins were partially differ- 
entiated 
F9 cells are induced to differentiate into parietal endo- 
derm cells upon treatment, in vitro, with RA and dbcAMP 
[61]. Differentiating cells undergo morphological changes, 
assuming a much more elongated shape and becoming 
more refractive, as shown in panel 2 in Fig. 2A. Cells of 
most clones that expressed a mutant form of the E1A 
protein were both more refractive and more elongated than 
undifferentiated F9 cells, with the exception of mB cells 
[F9 cells transfected with the gene construct for the mutant 
E1A protein with deletion of amino acids 51 to 116 
(A51-116)]. The morphology of mB cells, which expressed 
the mutant E1A protein A51-116, was similar to that of 
undifferentiated F9 cells (panel 4 in Fig. 2A). Unlike the 
differentiated F9 cells induced by treatment with RA, the 
E1A-expressing cells had the capacity for continued prolif- 
eration, although their growth rates were about 15-20% 
lower than that of undifferentiated F9 cells (Fig. 2B), and 
cells were capable of proliferating in culture for long 
periods of time. However, when these E1A-expressing 
cells were additionally incubated with RA, typical pheno- 
typic changes, for example, a completely differentiated 
morphology and a still lower growth rate were observed in 
the case of all of the clones examined in this study (data 
not shown). 
3.3. Appearance of markers of differentiation 
To extend the analysis of the differentiation phenotype 
of F9 clones that expressed the different E1A gene con- 
structs, we examined the expression of the cell-surface 
antigen SSEA-1, which is specific to undifferentiated stem 
cells, on the E1A-expressing clones in a comparison with 
both undifferentiated F9 cells and with F9 cells that had 
been induced to differentiate by treatment with RA (Fig. 
3). Most of the F9 mutant clones (mA, mC and mD) that 
expressed E1A proteins, resembling the differentiated F9 
cells induced by RA, failed to express the SSEA-1 marker. 
The level of expression of SSEA-1 by the mB clone 
(A51-116) was about 75% of that by the control, undiffer- 
entiated F9 cells. 
The levels of expression of several markers of differen- 
tiation, such as laminin B1, collagen type IV and tPA 
[44,45,62] were analyzed in F9 cells by Northern blotting 
(Fig. 4). In most EIA-expressing clones, as in the differen- 
tiated F9 cells that had been induced by RA, significant 
levels of mRNAs for tPA and laminin B1 were detected 
[62]. However, these mRNAs were not present at signifi- 
cant levels in the E1A mutant clones that expressed E1A 
protein that lacked the CR1 domain in addition to the 
spacer egion between CR1 and CR2 (A51-116). In the 
case of expression of laminin B 1, the F9 mA clone did not 
show enhanced levels of expression of the corresponding 
mRNA (lane 3 in panel B). Further treatment with RA of 
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A essential role in the ability of E1A to activate the transcrip- 
tion of known differentiation-associated g nes in F9 cells. 
3.4. Expression of the c-jun gene in clones with a mutant 
E1A 
10 7 B 
'~ 10 6 
~ 10 5 
10 4 I 
1 2 3 4 5 
Days 
Fig. 2. Morphology and growth rates of undifferentiated and differenti- 
ated F9 cells. Panel A, phase-contrast photomicrographs of F9 cells and 
clones that had been transfected with various Ad-5 E1A mutant con- 
structs. Panel 1, F9 cells; panel 2, F9 wild-type clone; panel 3, F9 mA 
clone; panel 4, F9 mB clone; panel 5, F9 mC clone; panel 6, F9 mD 
clone. Panel B, growth rates of F9 cells and of clones that had been 
transfected with various Ad-5 E1A mutant constructs. A total of 5 × 104 
cells was plated per tissue culture flask. On each of the following 4days, 
cell numbers were counted. Each point represents the mean (±S.D.) of 
results from triplicate flasks. (O), F9 EC cells; (0) F9 wild-type clone; 
(12), F9 mA clone; (zx) F9 mB clone; (It) F9 mC clone; (A) F9 mD 
clone. 
the mB and mA clones resulted in the efficient expression 
of mRNAs transcribed from these marker genes (data not 
shown). These results suggest hat the region that includes 
amino acids 51 to 116 of the E1A protein plays an 
We found previously that the EIA-mediated ifferentia- 
tion of F9 cells results in a large increase in the rate of 
transcription of the c-jun gene [47,51,52]. This induced 
transcription of the c-jun gene is caused by the E1A 
protein itself. Ectopic expression of the c-jun gene results 
in differentiation of EC cells, such as F9 and P19 cells 
[48-50,63], suggesting that the induction of transcription 
of the c-jun gene by E1A plays an important role in the 
differentiation process. Therefore, we examined the ex- 
pression of c-jun mRNA and the promoter activity of 
c-jun-CAT constructs in the clones that expressed mutant 
E1As. The levels of endogenous c-jun mRNA in most of 
the clones were from 10- to 100-fold greater than the 
levels in undifferentiated F9 cells, except in the case of the 
mB clone (Fig. 5). No significant changes in the level of 
/3-actin mRNA were observed (panel b). Similar results for 
expression of c-jun protein were obtained by Western 
blotting with an antibody against this protein (data not 
shown). The transcription of the c-jun gene is induced in 
E lA  transformants. Therefore, we suggested previously 
that E1A or an EIA-binding protein might directly or 
indirectly regulate the transcription of the c-jun gene. We 
characterized the sequence lements of the c-jun promoter 
that are required for the E1A-induced transcription of the 
c-jun gene. These elements are located in a region of 146 
bp between nucleotides -190  and -46  of the 5'-flanking 
region of the c-jun gene [53]. A recent study demonstrated 
that the most upstream portion ( -190  to -170)  of this 
region, designated the differentiation regulatory element 
(DRE), is neccessary for E1A-induced expression of the 
c-jun gene [53], [64] (also, IK, unpublished ata). There- 
fore, we examined the effects of the DRE of the c-jun 
promoter on E1A-mediated activation of c-jun. As shown 
in Fig. 6, most of the CAT constructs were associated with 
significant levels of CAT activity, as compared to that of 
control F9 cells, except in the case of the mB clone. The 
transcription of the c-jun-CAT construct was clearly due to 
the DRE since mutation of this element inhibited the 
activation of the c-jun promoter (see filled bar in Fig. 6). 
4. Discussion 
In the present study, we obtained evidence that constitu- 
tive expression of E1A mutant proteins, either with dele- 
tions of the amino-terminal region or with deletions of 
sequences in conserved regions 2 (CR2) and 3 (CR3), 
induced phenotypic hanges in F9 cells and alterations in 
the expression of cellular genes that are related to those 
that occur during the differentiation of F9 cells. By con- 
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trast, transformed F9 clone,; that lacked the sequence that 
included the CR1 domain and the spacer egion between 
the CR1 and CR2 domains (/151-116) failed to exhibit 
evidence of differentiation or the expression of the differ- 
entiation markers, suggesting that the region from amino 
acid position 51 to position 116 is necessary for the 
E1A-induced ifferentiation of F9 cells (Figs. 2-4). More- 
over, cells with the mutant E1A protein with deletion of 
amino acids 81 to 120 demonstrated increased expression 
of markers of differentiation and the disappearance of
SSEA-1 as a stem cell m~.rker (Figs. 2-4). Therefore, it 
appears that the sequence !in the carboxy-terminal half of 
the CR1 domain of the E1A protein (amino acids 51 to 81) 
is important for E1A-induced differentiation of F9 cells. 
Recent studies demonstrated that the amino-terminal re- 
gion and the carboxy-terminal half of the CR1 domain are 
both required for the binding of p300 to E1A [reviewed in 
[65]]. However, in the case of differentiation of F9 cells, 
the carboxy-terminal half of CR1 of the E1A protein might 
be required for the triggering of differentiation. 
There are conflicting observations about the role of 
E1A protein in the differentiation of F9 cells. Weigel et al. 
[60] reported that expression of 12S E1A blocked differen- 
tiation and resulted in cell lines that did not express 
markers of terminal differentiation in the presence of 
retinoic acid and cAMP. By contrast, Velcich and Ziff [45] 
and Montano and Lane [44] showed that E1A induced the 
differentiation of F9 cells. However, in our system, the 
cells with E1A mutant proteins expressed markers of 
terminal differentiation i the absence of RA (data not 
shown). The presence of the mutant EIA protein in these 
clones was not capable of interrupting the induction of 
differentiation by treatment with RA (data not shown). 
Furthermore, induction of the expression of the c-jun gene 
was observed. Therefore, we believe that the cellular and 
biochemical events in the F9 cells that had been trans- 
fected with the mutant constructs were those that occurr 
during the program that leads to differentiation, although 
we cannot rule out the possibility that they resulted from 
the alterations in the program that results in cell transfor- 
mation. 
Velcich and Ziff [45] and Weigel et al. [60] both 
reported that the frequency of formation of colonies by 
E1A-transformed clones was quite low. The extent of 
differentiation i  the few cell lines that did arise was 
clearly limited; the expression of only one marker of 
differentiation (endo A) was increased [45]. A possible 
explanation for these findings is that the E1A protein itself 
induces apoptosis. It is well known that apoptosis of F9 
cells, as a result of the presence of an intact E1A protein, 
can occur during cultivation [66-68]. Therefore, F9 clones 
transfected with wild-type E1A might tend to die, with 
resultant establishment of only a few clones or none at all. 
We cannot rule out, for this reason, the possibility that 
observations that the E1A protein suppresses differentia- 
tion of F9 cells might be due to a distinct property of E1A. 
It has also been reported that E1A blocks the induction of 
differentiation of PC12 cells [69-71] and of myoblasts 
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Fig. 3. FACS analysis of the cell-surface xpression of SSEA-1 on differentiated F9 clones that had been transfected with various Ad-5 E1A mutant 
constructs. Uninterrupted line, Sl~EA-l-specific mAb, KM-380; dotted line, antibodies against normal mouse IgG. Panel A, F9 cells; panel B, F9 wild-type 
clone; panel C, F9 mA clone; panel D, F9 mB clone; panel E, F9 mC clone; panel F, F9 mD clone. 
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[72,73]. However, we observed the delayed growth of cells 
and the induction of markers of differentiation upon fur- 
ther treatment of EIA-expressing cells with RA (data not 
shown). Moreover, transactivation f the c-jun gene was 
detected in F9 clones with mutant E IA proteins. Taken 
together, these observations suggest hat it is highly likely 
that the alterations in each F9 clone with an E1A mutant 
protein occurred on the pathway to cell differentiatioin. Of
course, further studies are needed to support his conclu- 
sion. 
Both the E1A mutant without amino acid residues 15 to 
35 in the amino-terminal region and the mutant 13S E1A 
without amino acid residues 121 to 151 were capable of 
a 
b 
1 2 3 4 5 6 
1 2 3 4 5 6 
4 
A 1 2 3 4 5 6 C 1 2 3 4 5 6 
B 1 2 3 4 s 6 
C 1 2 3 4 5 6 
D 1 2 3 4 5 6 
E 1 2 3 4 s 6 
Collagen IV 
Laminin B1 
tPA 
Actin 
Fig. 4. Northem blot analysis of RNA from F9 cells and clones that had 
been transfected with various Ad-5 E1A mutant constructs. Twenty-five 
/xg of total cellular RNA, except in the case of panel D, were subjected to 
electrophoresis on a 1.2% agarose gel, and bands were allowed to 
hybridize with [32p]-labeled DNA probes pecific for collagen type IV 
(panel A), laminin B 1 (panel B), and tissue-type lasminogen activator 
(tPA; panel C). In the case of panel D, 10/zg of total cellular RNA were 
subjected toelectrophoresis and allowed to hybridize with a [32p]-labeled 
DNA probe for fl-actin mRNA. To demonstrate loading of equivalent 
samples, bands of ribosomal RNA, 28S and 18S, are depicted for all 
Northern analyses (panel E). Lane 1, F9 cells; lane 2, F9 wild-type clone; 
lane 3, F9 mA clone; lane 4, F9 mB clone; lane 5, F9 mC clone; lane 6, 
F9 mD clone. 
Fig. 5. Expression of the c-jun gene in undifferentiated F9 cells and in 
differentiated F9 cells. Total RNA (10 p.g) was transferred, after elec- 
trophoresis, toa nylon membrane and allowed to hybridize to a fragment 
of c-jun cDNA [53], as probe, a, mRNA transcribed from the c-jun gene; 
b, mRNA for fl-actin. To demonstrate loading of equivalent samples, 
bands of ribosomal RNA, 28S and 18S, are depicted for all Northern 
analyses (c). Lane 1, F9 cells; lane 2, F9 wild-type clone; lane 3, F9 mA 
clone; lane 4, F9 mB clone; lane 5, F9 mC clone; lane 6, F9 mD clone. 
activating the transcription of genes for several markers of 
differentiation, aswell as the induction of differentiation f
F9 cells (Figs. 3 and 4). These results imply that the 
separate deletions of three regions of EIA, namely, the 
amino-terminal region, CR2 and CR3 do not affect E1A- 
induced differentiation. Only the mutant E1A protein that 
lacked CR1 and the spacer sequence between CR1 and 
CR2, which had lost the ability to bind both to the 300kDa 
protein and to the 105kDa pRB and pRB-like proteins, 
induced none of the phenotypic alterations associated with 
cell differentiation (Figs. 2-4). 
Several cellular promoters have been found to be acti- 
vated by the 12S E1A protein [65,75], and the conserved 
region 1 (CR1) of E1As appears to be essential for the 
trans-activation of genes. In a previous study we demon- 
strated that the level of expression of c-jun is well corre- 
lated with the E1A-induced ifferentiation of F9 cells [53]. 
The c-jun protein is believed to play a key role in the 
regulation of proliferation and differentiation of cells be- 
cause it mediates responses to a multitude of extra- and 
intracellular stimuli [46]. In addition, CR1 has been shown 
to be required for repression of the expression of collage- 
H.-O. Li et al. / Biochimica et Biophysica Acta 1266 (1995) 148-156 155 
Relative CAT activity (%) 
F9 
F9 + WT 
F9 + RA 
mA 
mB 
mC 
mD 
Fig. 6. CAT assays of undifferentiated F9 cells and differentiated F9 
cells. Relative promoter activities of -730/+874c-jun-CAT and 
- 730/+ 874c-jun-CATm182/175 (mDRE) constructs in undifferenti- 
ated and differentiated F9 cells. Normalized CAT activity due to 
-730/+874c- jun-CAT in F9 ceils that had been treated with RA 
(1 X 10 -6 M) was taken arbitrarily as 100%. All values for CAT activity 
are the averages of results from at least four transfections and standard 
deviations for each value are indicated. F9, Undifferentiated F9 cells; F9 
WT, F9 wild-type clone; F9 + RA, F9 ceils that had been treated with RA 
(1 X 10 -6 M) for 72 h. Cell lysates were prepared and CAT activity was 
analyzed, mA, roB, mC and mD refer to clones of F9 cells that had been 
transfected with mutant E1A constructs, as indicated in Fig. 1. The CAT 
activities of the -730/+874c-jun-CATm182/175 (mDRE) construct 
are indicated by filled bars. 
nase during the process of differentiation of F9 cells 
[74,75]. F9 cells themselves express an E1A-like activity, 
the repression of which is a component of the differentia- 
tion process, and the activity is involved in the control of 
cellular gene expression [76]. Our results of expression of 
c-jun gene imply the E1A without the carboxy-terminal 
region of the CRI sequence (A51-116) represses the in- 
trinsic E1A-like activity in F9 cells (Figs. 3-5). Moreover 
the study of the promoter activity of c-jun-CAT constructs 
on the clones that expres,;ed mutant E1As demonstrated 
that the levels of CAT activities in most of the clones were 
from 10- to 15-fold greater than that in undifferectiated F9 
cells, except in the case of the mB clone (Fig. 6). 
It has been reported thal binding of E1A to p300 can be 
selectively abolished by mutating the amino-terminal re- 
gion of E1A or the carboxy-terminal part of CR1 without 
any effect on the binding of E1A to any of the other 
known proteins with which it can associate [56,57]. How- 
ever, in case of the differentiation of F9 cells, only amino 
acids 51 to 80, which include the binding site of p300 
(amino acids 68 to 85) in CR1 of E1A (see Fig. 1), are 
associated with the induction of cell differentiation and 
activation of the c-jun gene. The fact that the activities of 
E1A can be mapped to CR1 leads us to propose that the 
induction of differentiation by E1A results from the ability 
of the protein to asssociate with certain cellular proteins, 
such as the 300kDa protein and pRb or pRb-related pro- 
teins, to activate and/or repress transcription of cellular 
regulatory genes, simultaneously, and to bring about the 
orderly differentiation of F9 cells. 
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